Lyme Opportunity InBios is actively developing a Lyme diagnostic test, presenting a potential entry point for sales discussions with researchers, hospitals, and clinics focusing on tick-borne disease diagnostics and regulatory approvals.

Strong ELISA Demand Recent launch of an in vitro serological ELISA kit for presumptive diagnosis of Strongyloides infection expands product line awareness and provides a pathway to cross-sell related serology and rapid test solutions to existing customers and new markets.

COVID Test Track Historically strong partnerships for COVID-19 rapid and antigen tests indicate a proven collaborative framework with distributors and defense/tederal channels, suggesting opportunities to re-engage these partners for current and future diagnostic pipelines.

Regulatory Credentials GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified positions InBios as a validated supplier for quality-conscious buyers, enabling outreach to large healthcare providers, reference laboratories, and government contracts seeking compliant vendors.

Mid-Market Fit Revenue range and employee size align with mid-market buyers, presenting a clear target for managed services, OEM collaborations, and contract manufacturing inquiries to scale production and accelerate go-to-market for diagnostic assays.